Diarrhea – MicrobiomePost

Lactobacillus rhamnosus CRL1505

Marco Marino — Thu, 29 Sep 2022 16:16:21 +0000

A randomized, double-blind, placebo-controlled trial with 298 pre-school children (2-5 years old) that consumed CRL 1505® (0,1 billion CFU/day) or a placebo 5 days/week for 6 months showed that children in the probiotic group had a significantly lower number of infections during the study period. CRL 1505® intake lowered the incidence of upper respiratory tract infections, pharyngitis, tonsillitis, and acute diarrhea. Additionally, kids in the probiotic group used less antibiotics.
One of the key elements identified in CRL 1505® interaction with the host is its heat-stable peptidoglycan (PG05), which has proven to have a strain-specific immunomodulatory activity. PG05 significantly increases specific antibodies production and the number of alveolar macrophages. These cells, during viral and bacterial infections, play a key role in the beneficial modulation of the respiratory innate immune response.
Lactobacillus rhamnosus CRL 1505® is given every day to more than 300,0000 children in Argentina as part of the official National Nutritional Program.

Lacidofil®

Staff — Wed, 13 Jul 2022 15:03:52 +0000

L. rhamnosus Rosell®-11 + L. helveticus Rosell®-52

Diarrhea, Antibiotic-Associated Diarrhea, H. pylori eradication therapy, Atopic Dermatitis

Lactose intolerance in children and adults
- 2B CFU

Atopic Dermatitis in children
- 2B CFU

Antibiotic-associated diarrhea in children and in adults
- from 1B to 12B depending on age

Adjunct to physician-supervised therapy in children and adults with Helicobacter pylori infections
- 4 to 6B CFU

Maintain a healthy microflora in pregnant women undergoing antibiotic therapy
- 4 to 6B CFU

Lacidofil®, a proprietary combination of Lactobacillus rhamnosus Rosell®-11 and Lactobacillus helveticus Rosell®-52, was developed more than 30 years ago by Lallemand Health Solutions to support and maintain the digestive microflora. Both the finished product formulation and the individual strains have been extensively used and researched worldwide over the years.

Bifidobacterium lactis Lafti® B94

Staff — Wed, 13 Jul 2022 13:41:51 +0000

The probiotic strain Bifidobacterium lactis Lafti® B94 has been specifically documented in the area of gut health. It benefits from a strong body of clinical evidence, supported by in vitro and in vivo documentation of its modes of action.

A converging body of clinical evidence: digestive comfort

Gut transit in all population groups (infants from birth, children, adolescents, adults):

Bifidobacterium animalis ssp lactis has shown to significantly decrease occasional constipation in adults and children/adolescents as well as other GI health benefits [Larsen et al. 2006; Favretto et al. 2013;Pitkälä 2007]. These studies showed that there were increases in stool frequency and decreases in stool consistency, improvement in normal defecation parameters and frequency compared to placebo. B. lactis LAFTI® B94 significantly improves bloating, belching–abdominal fullness and occasional constipation in children and teens [Basturk, 2016] and helps in occasional diarrhea in infants and children [Erdogan, 2012; Islek, 2014]

Based on two clinical studies in premature infants at risk for Necrotizing Enterocolitis (NEC) [Dilli, 2013; Dilli, 2015] B. lactis Lafti® B94 is safe for babies as it has a GRAS status in the US for use in infant milk formulas. It has also been granted health claims in Canada from birth.

Supportive mechanisms of action

B. lactis Lafti® B94 has been selected and fully documented for its probiotic features in in vitro and in vivo testing:

Survival through the digestive tract [Crittenden, 2001 ; Su, 2005].
Competition with other microorganisms: H. pylori, S. typhimurium, L. monocytogenes [Zhang, 2008; Crittenden, 2005; Mahoney, 2003].
Support of natural defenses [Peran, 2007 ; Pang, 2005].
Synergy with prebiotics: B. lactis Lafti® B94 has been selected among 40 Bifidobacterium isolates for its good synergy with a selection of probiotics among which inulin, FOS and GOS [Crittenden, 2001; Su, 2007].

Beyond gut health

B. lactis Lafti® B94 demonstrated its ability to activate bile acids metabolism in a clinical study involving 103 healthy overweight adults [Culpepper, 2019]

Lactobacillus delbrueckii P 18805

Staff — Fri, 08 Jul 2022 13:21:10 +0000

Allergy. Intestinal dysmicrobisms caused by antibiotic therapies. Diarrheal and dyspeptic syndromes due to altered bacterial flora (diarrhea, non-specific enteritis, colitis). Traveler’s diarrhea prevention.

They are deposited at the Laboratorium voor Microbiologie BCCM (Gent, Belgium). Deposit N°LMG P 18805.

Isolated from healthy human environment.

The microbial strain is not genetically modified and it is of natural origin (OMG Reg. (CE) 1829/2003 e 1830/2003).

Shelf-life raw material: 12 months when stored below -20°C or 6 months when stored below 8°C.

Also available as Active Pharmaceutical Product (API)

Lactobacillus acidophilus P 18806

Staff — Fri, 08 Jul 2022 13:21:10 +0000

Deposited at the Laboratorium voor Microbiologie BCCM (Gent, Belgium). Deposit N°LMG P 18806.

Isolated from healthy human environment.

The microbial strain is not genetically modified and it is of natural origin (OMG Reg. (CE) 1829/2003 e 1830/2003).

Shelf-life raw material: 12 months when stored below -20°C or 6 months when stored below 8°C.

*Also available as Active Pharmaceutical Product (API)

Streptococcus thermophilus P 18807

Staff — Fri, 08 Jul 2022 13:21:10 +0000

Deposited at the Laboratorium voor Microbiologie BCCM (Gent, Belgium). Deposit N°LMG P 18807.

Isolated from healthy human environment.

The microbial strain is not genetically modified and it is of natural origin (OMG Reg. (CE) 1829/2003 e 1830/2003).

Shelf-life raw material: 12 months when stored below -20°C or 6 months when stored below 8°C.

PS Mix®

Staff — Fri, 08 Jul 2022 11:13:24 +0000

Lactobacillus paracasei I 1688 + Lactobacillus salivarius I 1794 with vitamin B1 (0,6 mg) + vitamin B2 (0,5 mg). Ratio: 12:1

Restoration of the physiological intestinal balance. Pediatric gastroenteritis. Immunomodulatory activity in allergic patients (for asthma and allergic rhinitis). Induces a significant reduction of LDL cholesterol, as well as a significant improvement of the LDL / HDL ratio. Reduces the release of type 2 cytokines, induces an improvement in the th1 / th2 ratio.

Isolated from healthy human environment.

The microbial strains are not genetically modified and they are of natural origin (OMG Reg. (CE) 1829/2003 e 1830/2003).

12 months when stored below -20°C or 6 months when stored below 8°C.

Trix®

Staff — Fri, 08 Jul 2022 10:28:09 +0000

Lactobacillus plantarum P 17630 + Lactobacillus paracasei I 1688 + Lactobacillus salivarius I 1794 with vitamin B1 (0,6 mg) + vitamin B2 (0,5 mg). Ratio: 200:4.9:0.1

Intestinal dysbiosis. Leaky bowel syndrome. Health and well-being of the mucous membranes. Intestinal microflora imbalance: diarrhea, constipation, bloating, abdominal pain, intestinal gas production. Immunomodulating action, it acts on anti-inflammatory cytokines, helps reinforce the body’s natural defenses and rebalance the immune response. It assists the digestive processes of lactose in intolerant subjects.

Isolated from healthy human environment.

The microbial strains are not genetically modified and they are of natural origin (OMG Reg. (CE) 1829/2003 e 1830/2003).

Shelf life raw material: 12 months when stored below 8°C.

Lactobacillus rhamnosus – LR04 (DSM 16605)

Staff — Thu, 27 Jun 2019 14:35:45 +0000

Diarrhea • Inhibition of E. coli, including enterohemorrhagic O157:H7 • Cystitis • Inhibition of E. coli

Lactobacillus rhamnosus – GG (ATCC 53103)

Staff — Thu, 27 Jun 2019 14:24:22 +0000

Diarrhea • Rotaviral diarrhea • Gastroenteritis

Also available as Active Pharmaceutical Ingredient (API)

Autism and ADH prevention • Oral health • Caries prevention • Inhibition of Streptococcus mutans